Exelixis, Inc. (NASDAQ:EXEL) Holdings Trimmed by Phocas Financial Corp.

Phocas Financial Corp. cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 24.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 109,093 shares of the biotechnology company's stock after selling 35,689 shares during the quarter. Phocas Financial Corp.'s holdings in Exelixis were worth $3,633,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Exelixis by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after purchasing an additional 121,750 shares during the last quarter. LSV Asset Management increased its holdings in Exelixis by 0.8% during the 4th quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company's stock worth $272,056,000 after purchasing an additional 67,470 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in Exelixis by 10.2% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock worth $254,110,000 after purchasing an additional 708,312 shares during the last quarter. Invesco Ltd. increased its holdings in Exelixis by 308.1% during the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock worth $132,376,000 after purchasing an additional 3,001,204 shares during the last quarter. Finally, AQR Capital Management LLC grew its position in shares of Exelixis by 25.7% in the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock worth $132,101,000 after acquiring an additional 810,857 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Price Performance

NASDAQ:EXEL traded up $0.21 during midday trading on Friday, reaching $42.81. 3,886,221 shares of the company traded hands, compared to its average volume of 2,320,620. Exelixis, Inc. has a twelve month low of $21.18 and a twelve month high of $48.85. The firm has a market capitalization of $11.67 billion, a price-to-earnings ratio of 24.19, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. The company has a fifty day moving average price of $38.45 and a 200 day moving average price of $36.37.

Insider Activity at Exelixis

In other Exelixis news, EVP Dana Aftab sold 1,508 shares of the business's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the completion of the transaction, the executive vice president now owns 693,181 shares in the company, valued at approximately $27,034,059. The trade was a 0.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Tomas J. Heyman sold 4,544 shares of the business's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $44.29, for a total value of $201,253.76. Following the transaction, the director now owns 32,470 shares of the company's stock, valued at $1,438,096.30. This trade represents a 12.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold 441,740 shares of company stock worth $20,282,998 in the last 90 days. 2.82% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on EXEL shares. UBS Group reiterated an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. JMP Securities reiterated a "market outperform" rating and issued a $41.00 target price on shares of Exelixis in a research report on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Exelixis in a research report on Thursday, March 27th. Wells Fargo & Company reiterated a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Finally, Piper Sandler lifted their target price on Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Exelixis currently has an average rating of "Moderate Buy" and a consensus price target of $38.94.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.